Circassia said PAP-1, a novel topical therapeutic for psoriasis and atopic dermatitis, is a highly specific immunosuppressant and a selective Kv1.3 inhibitor that has ideal topical delivery characteristics.
According to a company-funded report published in the New England Journal of Medicine, both the drugs more than doubled the time that patients lived without their pancreatic neuroendocrine
The Phase II studies are designed to offer valuable insights to guide the selection of the therapeutic indications for which TC-6987 is best suited for later-stage development. The
The study results showed that two distinct twice-daily formulations of DM-1992 maintained therapeutic blood levels of levodopa over 24 hours, Depomed said. Both the formulations are projected, at
Tamiflu capsules are indicated for the treatment of bird and swine flu infections. Natco Pharma and Alvogen believe this is the first substantially completed ANDA filing containing a
UltraTape Industries is a division of Delphon and a supplier of cleanroom tape and labels to the medical/pharmaceutical, aerospace and semiconductor industries. The UltraLabel PRO is versatile and
According to Novo Nordisk, degludec reduces the risk of nocturnal hypoglycemia more than 35% compared with Lantus. Bloomberg.com has quoted Novo Nordisk chief science officer Mads Krogsgaard Thomsen
The recall is a consequence of Health Canada’s Good Manufacturing Practices (GMP) inspection at the company’s Laval manufacturing site where deficiencies in the production line were detected. Possible
Protect still retains the patents related to abuse deterrent and once daily gastro-retentive drug delivery platforms and the corresponding three other ongoing projects. In the near term, Protect
Bioject provides support for efforts to advance clinical research of intradermal delivery of vaccines in developing-country immunization programs to advance the use of DSJIs, reducing risks associated with
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.